HTR1A and Parkinson disease: Confirming the role of 5-HT1AR in the psychedelic experience, Pokorny and coworkers [81] found out that 5-HT1AR agonists such as buspirone reduce psilocybin-induced symptoms in humans, including visual hallucinations, derealization and depersonalization, via activation of 5-HT1AR and/or an interaction between 5-HT1A and 5-HT2A receptors, suggesting particular 5-HT1AR agonists could be useful for the treatment of schizophrenia and visual hallucinations in Parkinson’s disease.